Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590731547> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2590731547 endingPage "228" @default.
- W2590731547 startingPage "228" @default.
- W2590731547 abstract "228 Background: In our clinical data, we had the interesting findings that the pathologic sinusoidal obstruction syndrome and serum hyaluronic acid after neoadjuvant oxaliplatin-associated chemotherapy for liver metastatic colorectal cancer with bevacitumab (Bev) was ameliorated compared to those without Bev. The purpose of this study was to investigate the influence of bevacizumab administration on regenerating liver in rat 70% and 90% hepatectomy (Hx) model as a surrogate model of human massive hepatectomy for liver metastatic colorectal cancer. Methods: Male Wister rats weighing 180-230g were divided into the following four groups: 70%Hx, 70%Hx + Bev, 90%Hx and 90%Hx+Bev group. The rats were pretreated with intraperitoneal administration of bevacizumab (5mg/kg) 7 days before hepatectomy. The remnant liver and blood samples were taken one day after hepatectomy, and the following parameters were evaluated: blood analysis (AST, ALT, LDH, T- Bil, and hyaluronic acid), liver weight to body weight (Lw/Bw) ratio, and postoperative survival rate for three days. Results: In the 70%Hx model, there was no significant difference between the 70%Hx group and 70%Hx + Bev group in blood analysis one day after hepatectomy; AST (1928 vs. 923 IU/L), ALT (1282 vs. 670 IU/L), T-Bil (0.17 vs. 0.19 mg/dl), LDH (3822 vs. 2967 U/L) and hyaluronic acid (995.7 vs. 1026.6 ng/ml) and in Lw/Bw ratio (1.78 vs. 1.84). In 90%Hx model, AST and ALT of blood analysis in 90%Hx+Bev group significantly decreased compared to those in 90%Hx group; AST (3428 vs. 4995 IU/L, P<0.05), ALT (1471 vs. 2287 IU/L, P<0.05), T-Bil (1.94 vs. 2.57 mg/dl), LDH (3229 vs. 5351 U/L) and hyaluronic acid (3865.7 vs. 7862.2 ng/ml). The Lw/Bw ratio in 90%Hx+Bev group significantly increased compared to that in 90%Hx group (0.80 vs. 0.67, P<0.05). The postoperative survival rate in 90%Hx+Bev group showed tendency to improve compared to that in 90%Hx group (75% vs. 50%, P=0.19). Conclusions: The administration of bevacizumab seven days before hepatectomy did not significantly affect the liver functions and liver regeneration rate. These findings suggest that hepatectomy might be safe and feasible after the use of bevacizumab. No significant financial relationships to disclose." @default.
- W2590731547 created "2017-03-03" @default.
- W2590731547 creator A5004189291 @default.
- W2590731547 creator A5010934625 @default.
- W2590731547 creator A5019218267 @default.
- W2590731547 creator A5030227876 @default.
- W2590731547 creator A5048946839 @default.
- W2590731547 creator A5051158483 @default.
- W2590731547 creator A5054204391 @default.
- W2590731547 creator A5055604473 @default.
- W2590731547 creator A5058026310 @default.
- W2590731547 creator A5066565101 @default.
- W2590731547 date "2011-02-01" @default.
- W2590731547 modified "2023-09-25" @default.
- W2590731547 title "The impact of bevacizumab on liver regeneration following hepatectomy in rats." @default.
- W2590731547 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.228" @default.
- W2590731547 hasPublicationYear "2011" @default.
- W2590731547 type Work @default.
- W2590731547 sameAs 2590731547 @default.
- W2590731547 citedByCount "2" @default.
- W2590731547 countsByYear W25907315472017 @default.
- W2590731547 countsByYear W25907315472023 @default.
- W2590731547 crossrefType "journal-article" @default.
- W2590731547 hasAuthorship W2590731547A5004189291 @default.
- W2590731547 hasAuthorship W2590731547A5010934625 @default.
- W2590731547 hasAuthorship W2590731547A5019218267 @default.
- W2590731547 hasAuthorship W2590731547A5030227876 @default.
- W2590731547 hasAuthorship W2590731547A5048946839 @default.
- W2590731547 hasAuthorship W2590731547A5051158483 @default.
- W2590731547 hasAuthorship W2590731547A5054204391 @default.
- W2590731547 hasAuthorship W2590731547A5055604473 @default.
- W2590731547 hasAuthorship W2590731547A5058026310 @default.
- W2590731547 hasAuthorship W2590731547A5066565101 @default.
- W2590731547 hasConcept C105702510 @default.
- W2590731547 hasConcept C121608353 @default.
- W2590731547 hasConcept C126322002 @default.
- W2590731547 hasConcept C126894567 @default.
- W2590731547 hasConcept C141071460 @default.
- W2590731547 hasConcept C159110652 @default.
- W2590731547 hasConcept C171056886 @default.
- W2590731547 hasConcept C2776231280 @default.
- W2590731547 hasConcept C2776694085 @default.
- W2590731547 hasConcept C2776795407 @default.
- W2590731547 hasConcept C2776909242 @default.
- W2590731547 hasConcept C2777529286 @default.
- W2590731547 hasConcept C2777802072 @default.
- W2590731547 hasConcept C2780140570 @default.
- W2590731547 hasConcept C2780159080 @default.
- W2590731547 hasConcept C2780962732 @default.
- W2590731547 hasConcept C526805850 @default.
- W2590731547 hasConcept C71924100 @default.
- W2590731547 hasConcept C86803240 @default.
- W2590731547 hasConcept C90924648 @default.
- W2590731547 hasConcept C95444343 @default.
- W2590731547 hasConceptScore W2590731547C105702510 @default.
- W2590731547 hasConceptScore W2590731547C121608353 @default.
- W2590731547 hasConceptScore W2590731547C126322002 @default.
- W2590731547 hasConceptScore W2590731547C126894567 @default.
- W2590731547 hasConceptScore W2590731547C141071460 @default.
- W2590731547 hasConceptScore W2590731547C159110652 @default.
- W2590731547 hasConceptScore W2590731547C171056886 @default.
- W2590731547 hasConceptScore W2590731547C2776231280 @default.
- W2590731547 hasConceptScore W2590731547C2776694085 @default.
- W2590731547 hasConceptScore W2590731547C2776795407 @default.
- W2590731547 hasConceptScore W2590731547C2776909242 @default.
- W2590731547 hasConceptScore W2590731547C2777529286 @default.
- W2590731547 hasConceptScore W2590731547C2777802072 @default.
- W2590731547 hasConceptScore W2590731547C2780140570 @default.
- W2590731547 hasConceptScore W2590731547C2780159080 @default.
- W2590731547 hasConceptScore W2590731547C2780962732 @default.
- W2590731547 hasConceptScore W2590731547C526805850 @default.
- W2590731547 hasConceptScore W2590731547C71924100 @default.
- W2590731547 hasConceptScore W2590731547C86803240 @default.
- W2590731547 hasConceptScore W2590731547C90924648 @default.
- W2590731547 hasConceptScore W2590731547C95444343 @default.
- W2590731547 hasIssue "4_suppl" @default.
- W2590731547 hasLocation W25907315471 @default.
- W2590731547 hasOpenAccess W2590731547 @default.
- W2590731547 hasPrimaryLocation W25907315471 @default.
- W2590731547 hasRelatedWork W1121609380 @default.
- W2590731547 hasRelatedWork W2003080165 @default.
- W2590731547 hasRelatedWork W2098707609 @default.
- W2590731547 hasRelatedWork W2409507836 @default.
- W2590731547 hasRelatedWork W2501488762 @default.
- W2590731547 hasRelatedWork W2559747698 @default.
- W2590731547 hasRelatedWork W2590731547 @default.
- W2590731547 hasRelatedWork W2739211216 @default.
- W2590731547 hasRelatedWork W4361823821 @default.
- W2590731547 hasRelatedWork W4384520861 @default.
- W2590731547 hasVolume "29" @default.
- W2590731547 isParatext "false" @default.
- W2590731547 isRetracted "false" @default.
- W2590731547 magId "2590731547" @default.
- W2590731547 workType "article" @default.